Dose Escalating Study for Amphinex-based PCI of Bleomycin.

Summary

The primary goal of this extension study is to further investigate the tolerability and efficacy in a phase I setting in order to see whether lower doses than the initial study dose of 0.25 mg/kg bw Amphinex in Amphinex-based PCI of bleomycin will show a comparable or improved safety and tolerability profile in combination with comparable signs of efficacy.

Timeline

Start

2012-01

Primary completion

2012-10

Completion

2013-02

Drugs

Indications